Epithelial derived CTGF promotes breast tumor progression via inducing EMT and collagen I fibers deposition

Oncotarget

Volumn 6, Issue 28, 2015, Pages 25320-25338

  Zhu, Xiaoping ^a   Zhong, Jing ^a,b   Zhao, Zhen ^a,c   Sheng, Jianting ^a   Wang, Jiang ^a,d   Liu, Jiyong ^a,e   Cui, Kemi ^a   Chang, Jenny ^f   Zhao, Hong ^a   Wong, Stephen ^a,f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^d Tongji Hospital   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

breast cancer; collagen I fibers; connective tissue growth factor (CTGF); Epithelial mesenchymal transition (EMT); tumor necrosis factor receptor 1 (TNFR1) pathway

Indexed keywords

COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; TUMOR NECROSIS FACTOR RECEPTOR 1; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; CTGF PROTEIN, HUMAN; I KAPPA B; TNFRSF1A PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CARCINOMA; BREAST TUMOR; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; IMMUNOREACTIVITY; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOCRINE EFFECT; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL MOTION; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STROMA CELL; TIME FACTOR; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOCRINE COMMUNICATION; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE I; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE-FREE SURVIVAL; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B PROTEINS; KAPLAN-MEIER ESTIMATE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STROMAL CELLS; TIME FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944463294     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4659     Document Type: Article

References (55)

1. Khamis ZI, Sahab ZJ, Sang QX. Active roles of tumor stroma in breast cancer metastasis. International journal of breast cancer. 2012; 2012:574025.
2. Sheu BC, Chang WC, Cheng CY, Lin HH, Chang DY, Huang SC. Cytokine regulation networks in the cancer microenvironment. Frontiers in bioscience : a journal and virtual library. 2008; 13:6255-6268.
3. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410:50-56.
4. Neufeld G, Kessler O. Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer metastasis reviews. 2006; 25:373-385.
5. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. The Journal of clinical investigation. 2007; 117:1175-1183.
6. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. The Journal of clinical investigation. 2011; 121:3804-3809.
7. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nature reviews Immunology. 2002; 2:106-115.
8. Bezbradica JS, Medzhitov R. Integration of cytokine and heterologous receptor signaling pathways. Nature immunology. 2009; 10:333-339.
9. de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, Kuppen PJ, Tollenaar RA, Mesker WE. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triplenegative carcinoma patients. Breast cancer research and treatment. 2011; 125:687-696.
10. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. The New England journal of medicine. 2009; 360:790-800.
11. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. The New England journal of medicine. 2006; 355:560-569.
12. Moussad EE, Brigstock DR. Connective tissue growth factor: what's in a name? Molecular genetics and metabolism. 2000; 71:276-292.
13. Edwards LA, Woolard K, Son MJ, Li A, Lee J, Ene C, Mantey SA, Maric D, Song H, Belova G, Jensen RT, Zhang W, Fine HA. Effect of brain-and tumor-derived connective tissue growth factor on glioma invasion. Journal of the National Cancer Institute. 2011; 103:1162-1178.
14. Braig S, Wallner S, Junglas B, Fuchshofer R, Bosserhoff AK. CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration. British journal of cancer. 2011; 105:231-238.
15. Chang CC, Shih JY, Jeng YM, Su JL, Lin BZ, Chen ST, Chau YP, Yang PC, Kuo ML. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. Journal of the National Cancer Institute. 2004; 96:364-375.
16. Jiang CG, Lv L, Liu FR, Wang ZN, Liu FN, Li YS, Wang CY, Zhang HY, Sun Z, Xu HM. Downregulation of connective tissue growth factor inhibits the growth and invasion of gastric cancer cells and attenuates peritoneal dissemination. Molecular cancer. 2011; 10:122.
17. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR in primary breast cancers associated with more advanced features. Cancer research. 2001; 61:8917-8923.
18. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nature medicine. 2013; 19:1423-1437.
19. Graeber TG, Eisenberg D. Bioinformatic identification of potential autocrine signaling loops in cancers from gene expression profiles. Nature genetics. 2001; 29:295-300.
20. Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, Stephens RM, Yfantis HG, Lee DH, Weinstein JN, Ambs S. A stromal gene signature associated with inflammatory breast cancer. International journal of cancer Journal international du cancer. 2008; 122:1324-1332.
21. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M. Stromal gene expression predicts clinical outcome in breast cancer. Nature medicine. 2008; 14:518-527.
22. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer research. 2013; 73:4885-4897.
23. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nature reviews Cancer. 2013; 13:97-110.
24. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449:557-563.
25. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast cancer research : BCR. 2009; 11:R7.
26. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:15449-15454.
27. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704-715.
28. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes and development. 2001; 15:50-65.
29. Seewaldt V. ECM stiffness paves the way for tumor cells. Nature medicine. 2014; 20:332-333.
30. Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. The Journal of cell biology. 1991; 114:1285-1294.
31. Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. The international journal of biochemistry and cell biology. 2009; 41:771-783.
32. Jun JI, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nature reviews Drug discovery. 2011; 10:945-963.
33. Hall-Glenn F, Lyons KM. Roles for CCN2 in normal physiological processes. Cellular and molecular life sciences : CMLS. 2011; 68:3209-3217.
34. Dornhofer N, Spong S, Bennewith K, Salim A, Klaus S, Kambham N, Wong C, Kaper F, Sutphin P, Nacamuli R, Hockel M, Le Q, Longaker M, Yang G, Koong A, Giaccia A. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer research. 2006; 66:5816-5827.
35. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. The Journal of clinical investigation. 2001; 107:135-142.
36. Burstein B, Maguy A, Clement R, Gosselin H, Poulin F, Ethier N, Tardif JC, Hebert TE, Calderone A, Nattel S. Effects of resveratrol (trans-3,5,4'-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction. The Journal of pharmacology and experimental therapeutics. 2007; 323:916-923.
37. Sonnylal S, Xu S, Jones H, Tam A, Sreeram VR, Ponticos M, Norman J, Agrawal P, Abraham D, de Crombrugghe B. Connective tissue growth factor causes EMT-like cell fate changes in vivo and in vitro. Journal of cell science. 2013; 126:2164-2175.
38. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature reviews Cancer. 2002; 2:442-454.
39. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Developmental cell. 2008; 14:818-829.
40. Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis and tissue repair. 2012; 5. (Suppl 1 Proceedings of Fibroproliferative disorders: from biochemical analysis to targeted therapies-Petro E Petrides and David Brenner):S24.
41. Chen PS, Wang MY, Wu SN, Su JL, Hong CC, Chuang SE, Chen MW, Hua KT, Wu YL, Cha ST, Babu MS, Chen CN, Lee PH, Chang KJ, Kuo ML. CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway. Journal of cell science. 2007; 120:2053-2065.
42. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, Dargemont C, de Herreros AG, Bellacosa A, Larue L. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene. 2007; 26:7445-7456.
43. Tran CM, Shapiro IM, Risbud MV. Molecular regulation of CCN2 in the intervertebral disc: lessons learned from other connective tissues. Matrix biology : journal of the International Society for Matrix Biology. 2013; 32:298-306.
44. Elo TD, Valve EM, Seppanen JA, Vuorikoski HJ, Makela SI, Poutanen M, Kujala PM, Harkonen PL. Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice. Neoplasia. 2010; 12:915-927.
45. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Disease models and mechanisms. 2011; 4:165-178.
46. Zhang K, Corsa CA, Ponik SM, Prior JL, Piwnica-Worms D, Eliceiri KW, Keely PJ, Longmore GD. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nature cell biology. 2013; 15:677-687.
47. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486:346-352.
48. Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, Elizalde PV, Schillaci R. TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Experimental cell research. 2008; 314:509-529.
49. Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, Elford AR, Mak TW, Ohashi PS. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. The Journal of clinical investigation. 2007; 117:3833-3845.
50. Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, Nevins JR. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer research. 2011; 71:1772-1780.
51. Jacobson A, Cunningham JL. Connective tissue growth factor in tumor pathogenesis. Fibrogenesis and tissue repair. 2012; 5. (Suppl 1 Proceedings of Fibroproliferative disorders: from biochemical analysis to targeted therapiesPetro E Petrides and David Brenner):S8.
52. Cunningham JL, Tsolakis AV, Jacobson A, Janson ET. Connective tissue growth factor expression in endocrine tumors is associated with high stromal expression of alpha-smooth muscle actin. European journal of endocrinology / European Federation of Endocrine Societies. 2010; 163:691-697.
53. Zhao H, Jin G, Cui K, Ren D, Liu T, Chen P, Wong S, Li F, Fan Y, Rodriguez A, Chang J, Wong ST. Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases. Cancer research. 2013; 73:6149-6163.
54. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Science translational medicine. 2:43ra55.
55. Cheng J, Zhu X, Cheng H, Zhao H, Wong ST. A quantitative analysis of F-actin features and distribution in fluorescence microscopy images to distinguish cells with different modes of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual Conference. 2013; 2013:136-139.